What is KeyCorp’s Estimate for IDXX Q3 Earnings?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Analysts at KeyCorp issued their Q3 2026 earnings per share (EPS) estimates for IDEXX Laboratories in a note issued to investors on Sunday, October 11th. KeyCorp analyst S. Dechert expects that the company will earn $3.70 per share for the quarter. KeyCorp has a “Sector Weight” rating on the stock. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $14.81 per share. KeyCorp also issued estimates for IDEXX Laboratories’ Q4 2026 earnings at $3.34 EPS, FY2026 earnings at $14.77 EPS, Q1 2027 earnings at $3.93 EPS, Q2 2027 earnings at $4.61 EPS, Q3 2027 earnings at $4.22 EPS, Q4 2027 earnings at $3.81 EPS, FY2027 earnings at $16.58 EPS and FY2028 earnings at $18.74 EPS.

Several other analysts have also weighed in on the company. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group boosted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Barclays dropped their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Finally, Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Stock Down 0.7%

IDXX opened at $520.31 on Wednesday. IDEXX Laboratories has a one year low of $500.61 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock’s fifty day moving average is $536.72 and its 200-day moving average is $552.17. The company has a market capitalization of $40.99 billion, a PE ratio of 36.85, a P/E/G ratio of 2.80 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same period last year, the company posted $3.50 EPS. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.79% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds have recently made changes to their positions in the company. SHP Wealth Management acquired a new position in IDEXX Laboratories in the 4th quarter valued at $26,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the 2nd quarter worth $25,000. Elevation Wealth Partners LLC lifted its position in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after acquiring an additional 32 shares during the last quarter. Arlington Trust Co LLC lifted its position in IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after acquiring an additional 19 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new position in IDEXX Laboratories during the 4th quarter worth $46,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.